Following whole blood stimulation with mesenchymal stem cell derived exosomes, immune phenotype, cytokine release and mRNA expression patterns from critically ill patients with COVID-19 will be determined.
Critically ill patients with COVID-19 may develop lung failure and require extracorporal oxygenation due to hyperinflammation and progressive lung fibrosis. The anti-inflammatory and immune modulatory function of mesenchymal stem cells will be investigated by whole blood stimulation experiments using stem cell derived exosomes. Exosome preparations have been characterized by miRNA and protein expression patterns and suggest their tissue regenerative capacity. The hypothesis of the present study is that mesenchymal stem cell derived exosomes attenuate inflammation and support anti-fibrotic pathways.
Study Type
OBSERVATIONAL
Enrollment
40
Co-incubation of patient-derived whole blood samples with mesenchymal stem cell derived exosomes and read-out of biomarkers, RNA and immune phenotypes after 24h.
Ulm University Hospital, Clinic of Anesthesiology and Intensive Care Medicine
Ulm, Germany
RECRUITINGCytokine profile in supernatants
Quantification of pro- and anti-inflammatory biomarkers after 24 hours of whole blood culture
Time frame: 24 hours, 1 year
Immune phenotyping
Immune phenotypes related to type I interferon signaling
Time frame: 1 year
Genetic predisposition to hyperinflammation
Determination of functional single nucleotide polymorphisms of inflammatory genes and receptors
Time frame: 1 year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.